Background: Previous studies have suggested that African-American populations have a lower prevalence of Parkinson’s disease (PD); however, because African-Americans are underrepresented in many cohorts, this relationship is poorly understood. We evaluated data from the Reasons for Geographic and Racial Differences in Stroke (REGARDS) study to describe potential racial differences in PD prevalence. Methods: We identified subjects using PD medications from the REGARDS study, a national longitudinal cohort study of 30,000 persons over age 45 with approximately equal representation of African-Americans and Whites. Results: The prevalence of PD medication use across the cohort was 0.78% and was less among African-Americans (0.51%) than among Whites (0.97%; OR 1.90; 95% CI 1.31–2.74). There was an association of gender and PD medication use, with a prevalence of 0.61% in females and 0.97% in males (OR 1.57; 95% CI 1.13–2.18). There was no association with income, education level or geographic region of residence. Conclusions: The lower rate of PD medication use among African-Americans supports the suspected lower prevalence of PD among African-Americans suggested by other studies. While racial differences in PD diagnosis and treatment may contribute to the differences we observed, comparable disparities have not been observed in the REGARDS cohort for other diagnoses. Further studies of the REGARDS cohort may lead to important insights into potential biological differences in PD among African-Americans and Whites.

Keywords:
Parkinson’s disease, Reasons for Geographic and Racial Differences in Stroke study, Cohort studies
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.